Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

    Date Summary View
    Toggle Summary RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
    YELIVA ® , a proprietary, first-in-class SK2 inhibitor, was granted FDA Orphan Drug designation for the treatment of cholangiocarcinoma Cholangiocarcinoma (bile duct cancer) is a highly lethal malignancy for which there is an urgent need for more effective treatments A Phase I clinical study with ...
    View HTML
    Toggle Summary RedHill Biopharma Provides 2017 Year-End Business Update
    TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 05, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Reports 2017 Third Quarter Financial Results
    RedHill maintains a debt-free balance sheet with $39.6 million in cash 1 at the end of the third quarter of 2017 In addition, an underwritten public offering of the Company's American Depositary Shares (ADSs) is scheduled to be closed today, November 13, 2017 , subject to customary terms and ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease
    Top-line results are expected to be announced in mid-2018   The Phase III study evaluating RHB-104 for Crohn's disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active ...
    View HTML
    Toggle Summary RedHill Biopharma Prices Public Offering of its American Depositary Shares
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma to Host Third Quarter 2017 Financial Results Conference Call on November 13, 2017
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma Announces EnteraGam® Poster Presentation at the ISPOR 20th Annual European Congress
    TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
    View HTML
    Toggle Summary RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT® for Migraines
    RIZAPORT ® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines A Prescription Drug User Fee Act (PDUFA) date is expected to be set by the FDA for the first half of 2018, if the submission is deemed complete and permits a full review RIZAPORT ® (5mg and ...
    View HTML